BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 15719440)

  • 1. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.
    Chirieac LR; Swisher SG; Ajani JA; Komaki RR; Correa AM; Morris JS; Roth JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2005 Apr; 103(7):1347-55. PubMed ID: 15719440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
    Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma.
    Korst RJ; Kansler AL; Port JL; Lee PC; Kerem Y; Altorki NK
    Ann Thorac Surg; 2006 Aug; 82(2):480-4; discussion 484-5. PubMed ID: 16863749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
    Chirieac LR; Swisher SG; Correa AM; Ajani JA; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Clin Cancer Res; 2005 Mar; 11(6):2229-36. PubMed ID: 15788671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma.
    Gaca JG; Petersen RP; Peterson BL; Harpole DH; D'Amico TA; Pappas TN; Seigler HF; Wolfe WG; Tyler DS
    Ann Surg Oncol; 2006 Mar; 13(3):340-6. PubMed ID: 16485154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
    Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
    Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
    Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
    Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus.
    Rohatgi PR; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh G; Vaporciyan A; Lynch PM; Rice DC; Roth JA; Ajani JA
    Cancer; 2005 Oct; 104(7):1349-55. PubMed ID: 16130133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation.
    Wang KL; Yang Q; Cleary KR; Swisher SG; Correa AM; Komaki R; Ajani JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Oct; 107(7):1467-74. PubMed ID: 16955509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.
    Kesler KA; Helft PR; Werner EA; Jain NP; Brooks JA; DeWitt JM; Leblanc JK; Fineberg NS; Einhorn LH; Brown JW
    Ann Thorac Surg; 2005 Apr; 79(4):1116-21. PubMed ID: 15797035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus.
    Donington JS; Miller DL; Allen MS; Deschamps C; Nichols FC; Pairolero PC
    Ann Thorac Surg; 2004 Apr; 77(4):1193-8; discussion 1198-9. PubMed ID: 15063233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
    Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
    J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Saltz LB; Goodman KA; Minsky BD; Wong WD; Weiser MR
    Cancer; 2008 Jul; 113(1):57-64. PubMed ID: 18442099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.
    Rohatgi PR; Mansfield PF; Crane CH; Wu TT; Sunder PK; Ross WA; Morris JS; Pisters PW; Feig BW; Gunderson LL; Ajani JA
    Cancer; 2006 Oct; 107(7):1475-82. PubMed ID: 16944539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
    Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.
    Berger AC; Farma J; Scott WJ; Freedman G; Weiner L; Cheng JD; Wang H; Goldberg M
    J Clin Oncol; 2005 Jul; 23(19):4330-7. PubMed ID: 15781882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.